Lenalidomide

Consolidation treatment before maintenance therapy improved outcomes among transplant-eligible patients with newly diagnosed multiple myeloma, according to study results presented at the virtual ASH Annual Meeting and Exposition.

The addition of daratumumab to lenalidomide, bortezomib and dexamethasone benefitted Black patients with transplant-eligible newly diagnosed multiple myeloma, according to data presented at Society of Hematologic Oncology Annual Meeting.

The addition of ixazomib to lenalidomide and dexamethasone did not significantly extend PFS among transplant-ineligible patients with newly diagnosed multiple myeloma, according to study results presented at Society of Hematologic Oncology Annual Meeting.

The FDA granted accelerated approval to tafasitamab-cxix in combination with lenalidomide for treatment of certain adults with pretreated diffuse large B-cell lymphoma.

Induction therapy with lenalidomide, bortezomib and dexamethasone demonstrated high response rates after transplantation among 90% of a cohort of patients with myeloma, according to study results published in Journal of Clinical Oncology.

March is Myeloma Awareness Month.

Patients with multiple myeloma who received lenalidomide-based regimens appeared to have considerable risk for venous thromboembolism, regardless of adequate thromboprophylaxis, according to study results published in Cancer.

A randomized phase 3 trial designed to evaluate the addition of ixazomib to lenalidomide and dexamethasone for patients with newly diagnosed multiple myeloma ineligible for transplant failed to meet its primary endpoint, according to the agent’s manufacturer.

A randomized phase 3 trial designed to evaluate the addition of elotuzumab to lenalidomide and low-dose dexamethasone for a subset of patients with multiple myeloma failed to meet its primary endpoint, according to the agent’s manufacturer.

The FDA granted priority review to tafasitamab in combination with lenalidomide for treatment of patients with relapsed or refractory diffuse large B-cell lymphoma, according to the agent’s manufacturer.